All In Biotech

NDA 218158 · Harrow Eye

Byqlovi

Clobetasol Propionate · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Apr 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Mar 4, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

119

23 Phase 3, 10 recruiting

FAERS reports

10,595

4,972 serious, 439 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 26, 2026.

BYQLOVI is indicated for the treatment of post-operative inflammation and pain following ocular surgery. BYQLOVI is a corticosteroid indicated for the treatment of post- operative inflammation and pain following ocular surgery. ( 1 )

Mechanism: Like other topical corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 4, 2024 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • BYQLOVI · CLOBETASOL PROPIONATE 0.05% · SUSPENSION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Clobetasol Propionate" as an intervention, any sponsor and status, largest first.

All 119 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,087
  • pruritus983
  • off label use682
  • rash676
  • product use in unapproved indication553
  • psoriasis550
  • fatigue531
  • headache501
  • diarrhoea448
  • nausea441
  • dry skin423
  • arthralgia421

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200520
200658
200792
200895
2009125
2010135
2011215
2012318
2013162
2014185
2015346
2016403
2017536
2018459
2019471
2020558
2021604
2022920
20231,216
20241,152
20251,320
20261,188

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 257 on PubMed

Sponsor: Harrow Eye

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.